Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A trial to investigate the efficacy and safety of SER-109 in patients with recurrent Clostridium difficile infections

Next Previous
X
Search
Trial Profile

A trial to investigate the efficacy and safety of SER-109 in patients with recurrent Clostridium difficile infections

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SER 109 (Primary)
  • Indications Clostridium difficile infections
  • Focus Therapeutic Use
  • Sponsors Seres Health

    • Most Recent Events

    • 07 Oct 2018 Results presented at the IDWeek 2018
    • 08 Oct 2017 Results of this trial and another one (refer CTP: 700247175) assessing gut microbiome changes were presented at the IDWeek 2017
    • 25 Feb 2016 According to Seres Therapeutics media release, the FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top